NEW DELHI: A combination of immunotherapy with chemotherapy, prior to surgery, to treat patients of triple negative breast cancer (TNBC), an aggressiv.
A recent study published in The Lancet Regional Health - Southeast Asia journal indicates that a higher dose of the COVID-19 drug, dexamethasone, may have varying effects for patients in India compared to those in Europe. The research focused on assessing the efficacy of a robust dose of dexamethasone in treating COVID-19 patients, considering factors such as patient differences and health systems.
ImmunoACT has portfolio of Chimeric Antigen Receptor T cells (CAR-T cells) therapy assets under various development stages for the treatment of multiple auto immune diseases and oncology indications.